Stay updated on Flotetuzumab in PIF/ER AML Clinical Trial
Sign up to get notified when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.

Latest updates to the Flotetuzumab in PIF/ER AML Clinical Trial page
- Check6 days agoChange DetectedNo significant changes were detected on the Study Details page for NCT02152956; the title, URL, and primary content appear unchanged.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check35 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference2%

- Check42 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top element was removed. This is a minor metadata/UI change with no impact on core content, pricing, stock, or time slots.SummaryDifference0.1%

- Check63 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check70 days agoChange DetectedThe web page has been updated to include new drug information for Ruxolitinib and relevant medical topics related to leukemia, while also changing the facility name and location details. Previous location details and certain genetic disease resources have been removed.SummaryDifference2%

Stay in the know with updates to Flotetuzumab in PIF/ER AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in PIF/ER AML Clinical Trial page.